A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis-Reference-Cited by-同舟云学术

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

Published:2021-05 Issue:5 Volume:29 Page:654-666
ISSN:1063-4584
Container-title:Osteoarthritis and Cartilage
language:en
Short-container-title:Osteoarthritis and Cartilage

Author:

Yazici Y.,McAlindon T.E.,Gibofsky A.,Lane N.E.,Lattermann C.,Skrepnik N.,Swearingen C.J.,Simsek I.,Ghandehari H.,DiFrancesco A.,Gibbs J.,Tambiah J.R.S.,Hochberg M.C.

Publisher

Elsevier BV

Subject

Orthopedics and Sports Medicine,Biomedical Engineering,Rheumatology

Reference41 articles.

1. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study;Cross;Ann Rheum Dis,2014

2. Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGF-β1);Zhang;Bone Joint Res,2018

3. Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis;Lin;Ann Rheum Dis,2016

4. Wnt/β-catenin signaling in osteoarthritis and in other forms of arthritis;Zhou;Curr Rheumatol Rep,2017

5. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis;Bannuru;Osteoarthr Cartil,2019

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orthobiologics—growth factors and mediators;OrthoBiologics;2025

2. New therapeutic strategies in osteoarthritis;Joint Bone Spine;2024-12

3. Intra-articular sustained-release of pirfenidone as a disease-modifying treatment for early osteoarthritis;Bioactive Materials;2024-09

4. A Review of Current Approaches to Pain Management in Knee Osteoarthritis with a Focus on Italian Clinical Landscape;Journal of Clinical Medicine;2024-08-31

5. A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion;Expert Opinion on Emerging Drugs;2024-08-05